title: [Current status of thrombolysis. The need for coadjuvant antithrombotic therapy].
abstract: Thrombolytic therapy yields a 80% repermeabilitation in the acute myocardium infarct if applied soon. In other thrombotic sites such as deep venous thrombosis, pulmonary thromboembolism and peripheral arterial thrombosis, with no large cooperative randomized clinical trials, its usefulness is clear, tough selectively. The high rethrombosis frequency is the major drawback of this therapy. The concomitant use of an anti-thrombotic and/or anti-aggregant agent, even tough the possible higher risks of hemorrhages, seems a key element to improve the results obtained with thrombolysis.
authors.affiliation: Servicio de Hematología, Hospital Ramón y Cajal, Madrid.
authors.forename: L J
authors.initials: LJ
authors.lastname: García Frade
authors.forename: A
authors.initials: A
authors.lastname: García Avello
mesh_terms: D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005544:Forecasting; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy; D012008:Recurrence; D015912:Thrombolytic Therapy / Q000379:methods*; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy
chemical_list: D005343:Fibrinolytic Agents
vernacular_title: Estado actual de la trombolisis. Necesidad de la terapéutica antitrombótica coadyuvante.